P
PRME icon

&Partners’s Prime Medicine PRME Stock Holding History

&Partners’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$207K Sell
59,470
-882
-1% -$3.36K ﹤0.01% 2232
2025
Q4 		$209K Buy
60,352
+48,504
+409% +$216K ﹤0.01% 2123
2025
Q3 		$70.6K Buy
+11,848
New +$48.1K ﹤0.01% 2069

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

&Partners's PRME Position: Q1 2026 in Review

&Partners reduced its Prime Medicine (PRME) stake by 1.5% in Q1 2026, selling an estimated $3.36K and leaving 59,470 shares worth $207K. The position accounts for ﹤0.01% of the portfolio, ranked #2232.

&Partners first reported a position in PRME in Q3 2025 and has held it in 3 quarters since. The position peaked at $209K in Q4 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • &Partners held 59,470 shares of Prime Medicine worth $207K as of Q1 2026.
  • &Partners sold 882 Prime Medicine shares in Q1 2026, an estimated $3.36K.
  • Prime Medicine made up ﹤0.01% of &Partners's portfolio in Q1 2026, its #2232 holding.
  • &Partners first reported a position in Prime Medicine in Q3 2025 and has held it in 3 quarters since.
  • &Partners's Prime Medicine position peaked at $209K in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.